Anebulo Pharmaceuticals, Inc.

DB:214 Stock Report

Market Cap: €42.3m

Anebulo Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:214 Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
23 Dec 24Buy€9,618,00022NW, LPCompany10,101,010€0.95

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 214?
Owner TypeNumber of SharesOwnership Percentage
Institutions1,977,8105.8%
Hedge Funds15,467,30045.4%
Individual Insiders16,654,52848.8%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 16 shareholders own 131.49% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
59.6%
22NW, LP
15,467,300€25.2m188%14.89%
46.3%
Joseph Lawler
12,000,000€19.6m0%no data
18%
Aron English
4,654,528€7.6m0%no data
2.47%
LVW Advisors, LLC
641,039€1.0m-0.16%0.13%
1.97%
Nantahala Capital Management, LLC
511,073€833.3k0%0.06%
1.54%
Morgan Stanley, Investment Banking and Brokerage Investments
399,219€650.9k0%no data
0.61%
Ikarian Capital, LLC
157,862€257.4k0%0.07%
0.59%
The Vanguard Group, Inc.
154,036€251.2k0.11%no data
0.34%
Geode Capital Management, LLC
87,790€143.1k71.1%no data
0.073%
Boothbay Fund Management, LLC
18,978€30.9k0%no data
0.015%
BlackRock, Inc.
3,905€6.4k3.83%no data
0.01%
Tower Research Capital Europe Limited
2,694€4.4k-18.4%no data
0.0029%
UBS Asset Management AG
763€1.2k0%no data
0.0014%
Lord, Abbett & Co. LLC
366€596.20%no data
0.00029%
Bank of America Corporation, Asset Management Arm
76€122.616.9%no data
0.00003%
JPMorgan Chase & Co, Brokerage and Securities Investments
9€12.7-10%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 13:57
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Anebulo Pharmaceuticals, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert WassermanBenchmark Company